Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/9/2025

Novolog 70/30 Dosing Protocol

Initial Dosing

  • The American Diabetes Association recommends starting with 10 units or 0.1-0.2 units/kg of body weight per day, divided into two equal doses, for patients initiating Novolog 70/30 therapy 2, 1
  • The typical administration schedule is twice daily, 30 minutes before breakfast and dinner, as recommended by the American College of Endocrinology 1

Dose Titration

  • The American Association of Clinical Endocrinologists suggests setting a fasting plasma glucose target and increasing the dose by 2 units every 3 days if 50% of fasting glucose readings are above target 2, 1
  • In cases of hypoglycemia, the dose should be decreased by 10-20%, as recommended by the Endocrine Society 2
  • Glycemic control should be evaluated every 2 weeks and therapy adjusted as needed, according to the American Diabetes Association 1

Administration Schedule

  • The American College of Physicians recommends administering Novolog 70/30 twice daily, with morning and evening doses, 30 minutes before breakfast and dinner 3, 1

Special Considerations

  • For patients receiving enteral bolus feedings, the American Diabetes Association suggests administering approximately 1 unit of insulin per 10-15g carbohydrate before each feeding 4
  • Patients on glucocorticoid therapy may require higher doses, particularly for daytime hyperglycemia, as recommended by the Endocrine Society 4
  • When transitioning from basal insulin, the total daily dose can be divided into two equal doses of Novolog 70/30, according to the American Association of Clinical Endocrinologists 2

Treatment Intensification

  • If glycemic targets are not achieved with twice-daily dosing, consider advancing to three-times-daily premixed insulin or switching to a basal-bolus regimen, as recommended by the American College of Endocrinology 1, 3
  • Adding a GLP-1 receptor agonist may be appropriate in certain cases, according to the American Diabetes Association 2, 1